Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 8/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10313867 | 0.85 | USP30 (0.48) | KCNH2USP30 | |
| SCHEMBL4149910 | 0.81 | IDO1 (0.47) | MAPTTP53THRBUSP30PIK3CA | |
| SCHEMBL4140613 | 0.78 | CYP2C9 (0.44) | — | |
| SCHEMBL4436095 | 0.75 | KCNH2 (0.52) | KCNH2 | |
| SCHEMBL4143197 | 0.75 | KCNH2 (0.52) | KCNH2 | |
| SCHEMBL3229809 | 0.75 | KCNH2 (0.52) | KCNH2 | |
| SCHEMBL5746081 | 0.75 | MAPT (0.42) | KCNH2MAPTTP53THRBUSP30 | |
| SCHEMBL5747966 | 0.75 | NAMPT (0.40) | MAPTTP53THRBPIK3CALMNA | |
| SCHEMBL6079335 | 0.74 | KCNH2 (0.41) | KCNH2 | |
| SCHEMBL6079826 | 0.73 | KCNH2 (0.38) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060041123-A1 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041123-A1 | Antibacterial agents | NQO2, NRDC, IFNG | KCNH2 3365/4885MAPT 4448/4885TP53 2210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.